1st patient treated in Kuros Biosciences spinal fusion trial

Alan Condon -   Print  |

Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease.

Fibrin-PTH is a drug-biologic that promotes bone growth through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and increasing the lifespan of bone-forming cells.

University of California San Diego's Richard Allen, MD, PhD, principal investigator of the study, treated the first patient.

The phase 2 study is evaluating the technology for both open and minimally invasive surgical techniques.

Fifty patients will be enrolled in the trial, with those treated with local autograft acting as controls.

More articles on biologics:
Meet Elon Musk's surgical robot
Laser Spine Institute 18 months after closure — What happened to its $56M Tampa HQ?
Vertebral body tethering shows success in the treatment of scoliosis, study finds

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers